When it comes to short-term investing or trading, they say "the trend is your friend." And there's no denying that this is the most profitable strategy. But making sure of the sustainability of a trend to profit from it is easier said than done.Often, the direction of a stock's price movement reverses quickly after taking a position in it, making investors incur a short-term capital loss. So, it's important to ensure that there are enough factors -- such as sound fundamentals, positive earnings estimate rev ...

For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Ligand Pharmaceuticals (LGND) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.Ligand Pharmaceuticals is a member of the Medical sector. This grou ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ________________________________________________________________________________________ FORM 10-Q ________________________________________________________________________________________ ☒ Quarterly Report Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2024 or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Transition Pe ...

Ligand Pharmaceuticals Incorporated (LGND) reported core adjusted diluted net income per share of $1.20 in first-quarter 2024 from continuing operations. Although earnings declined 10% year over, the figure still beat the Zacks Consensus Estimate of $1.13.Total revenues of $31.0 million were down 30% from the year-ago quarter’s levels. The reported figure missed the Zacks Consensus Estimate of $32.5 million.The downside in earnings and sales was due to the receipt of a milestone payment from Travere Therape ...

Ligand Pharmaceuticals (LGND) came out with quarterly earnings of $1.20 per share, beating the Zacks Consensus Estimate of $1.13 per share. This compares to earnings of $2.28 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 6.19%. A quarter ago, it was expected that this drugmaker would post earnings of $0.58 per share when it actually produced earnings of $1.05, delivering a surprise of 81.03%.Over the last four quarters, the ...

| --- | --- | --- | --- | |-------|--------------------------|--------------------------------------------------------------|-------| | | | | | | | LIGAND Financial Results | Biopharma's Technology andCapitalPartner First Quarter 2024 | | | | | | | This presentation contains forward-looking statements by Ligand and its partners that involve risks and uncertainties and reflect Ligand's and its partners' judgment as of the date of this presentation. Words such as "plans," "believes," "expects," "anticipates," ...

Ligand Reports First Quarter 2024 Financial Results Conference Call Begins at 4:30 p.m. Eastern Time Today Cost of Captisol was $2.9 million for the first quarter of 2024, compared with $3.7 million for the same period in 2023, with the decrease due to lower total Captisol sales. Amortization of intangibles was $8.2 million for the first quarter of 2024, compared with $8.5 million for the same period in 2023. Research and development expense was $6.0 million for the first quarter of 2024, compared with $6.7 ...

Thanks to the Magnificent Seven, tech stocks have led the Q1 earnings season. In fact, as Sheraz Mian the Director of Zacks Investment Research points out, had it not been for the substantial earnings contribution of the Mag 7, Q1 earnings growth for the rest of the S&P 500 index would be in negative territory.That said, several top-rated Zacks Medical sector stocks are standing out ahead of their Q1 reports on Tuesday, May 7. With now looking like an ideal to invest in their growth, here are three of these ...

AndreyPopovThis is my sixth article on royalty aggregator Ligand Pharmaceuticals (NASDAQ:LGND). My most recent previous Ligand article was 06/2023's "Ligand Pharmaceuticals: The New Ligand ("New Ligand"). In it I rated Ligand as a "Buy". At the time it was selling for $76.42. As I write on 04/21/2024 Ligand currently trades at ~$70.00, down ~8%. I continue to rate Ligand at a "Buy" because of its recent streamlining moves as discussed in this article. I view it as a better investment now because of thes ...

Ligand Pharmaceuticals (LGND) closed the last trading session at $79.92, gaining 10.7% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $116.33 indicates a 45.6% upside potential.The mean estimate comprises three short-term price targets with a standard deviation of $25.11. While the lowest estimate of $95 indicates an 18.9% increase from the current price level, the most optimistic ...